Overview

Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To demonstrate the safety and effectiveness of orally-administered pyridoxal isonicotinoyl hydrazone (PIH) for the chronic treatment of iron overload.

Phase:

Phase 2

Details

Lead Sponsor:

Case Western Reserve University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Pyridoxal isonicotinoyl hydrazone